Psychopharmref

Psychopharmref

Psychopharmacology and psychiatry

DEA raises 2026 stimulant quotas under the shortage law

Nov 20, 2026

•

4 min read

DEA raises 2026 stimulant quotas under the shortage law

Amphetamine ceilings up about 31% to 40%, methylphenidate about 19%. Whether pharmacies see it depends on manufacturers.

Jerad Shoemaker MD
Jerad Shoemaker MD
Psilocybin reaches the FDA: COMP360's application is complete

Nov 13, 2026

•

3 min read

Psilocybin reaches the FDA: COMP360's application is complete

Two Phase 3 wins, modest effect sizes, and a DEA step still ahead.

Jerad Shoemaker MD
Jerad Shoemaker MD
Centanafadine lands Schedule III as first triple reuptake inhibitor for ADHD

Nov 6, 2026

•

4 min read

Centanafadine lands Schedule III as first triple reuptake inhibitor for ADHD

What the DEA's October 2026 interim final rule means for prescribing access amid the ongoing stimulant shortage.

Jerad Shoemaker MD
Jerad Shoemaker MD
FDA clears first digital therapeutic for schizophrenia negative symptoms

Oct 30, 2026

•

3 min read

FDA clears first digital therapeutic for schizophrenia negative symptoms

Motivista's 510(k) clearance covers negative symptoms of schizophrenia, an indication no drug holds in the US.

Jerad Shoemaker MD
Jerad Shoemaker MD
RAP-219 hits Phase 2 primary endpoint in acute bipolar mania

Oct 23, 2026

•

4 min read

RAP-219 hits Phase 2 primary endpoint in acute bipolar mania

A TARPγ8-selective AMPA modulator challenges dopamine-centered antimanic pharmacology.

Jerad Shoemaker MD
Jerad Shoemaker MD
Weltruza: Subcutaneous Olanzapine Drops the 3-Hour REMS Watch

Oct 16, 2026

•

4 min read

Weltruza: Subcutaneous Olanzapine Drops the 3-Hour REMS Watch

Weltruza skips post-injection monitoring; Elixir Sulfanilamide explains why that still needs scrutiny.

Jerad Shoemaker MD
Jerad Shoemaker MD
Load more